Close Menu

NEW YORK – A triple-pronged therapy that simultaneously targets BRAF, EGFR, and MEK seems to stretch out overall survival times in BRAF-mutated metastatic colorectal cancer cases, according to results from a randomized Phase III clinical trial called BEACON.

"We're hopeful that this will give new options for our [BRAF-mutated metastatic CRC] patients," said Scott Kopetz, a gastrointestinal medical oncologist at the University of Texas MD Anderson Cancer Center, principal investigator on BEACON and co-lead for MD Anderson's Cancer Moon Shot effort in CRC.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Apr
27
Sponsored by
Biognosys

This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.

Jun
16
Sponsored by
Biognosys

This webinar, the second in our Next-Generation Proteomics for Precision Oncology series, will discuss how unbiased discovery proteomics can be used to identify new key mechanisms and signatures supporting clinical decision-making for melanoma patients.